Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study

被引：0
|
作者：
William B. Young
J. Ivan Lopez
John F. Rothrock
Amelia Orejudos
Aubrey Manack Adams
Richard B. Lipton
Andrew M. Blumenfeld
机构：
[1] Jefferson Hospital for Neuroscience,
[2] University of South Alabama College of Medicine,undefined
[3] George Washington School of Medicine,undefined
[4] Allergan plc,undefined
[5] Montefiore Headache Center,undefined
[6] Department of Neurology,undefined
[7] Department of Epidemiology and Population Health,undefined
[8] Albert Einstein College of Medicine,undefined
[9] Headache Center of Southern California,undefined
[10] The Neurology Center,undefined
来源：
The Journal of Headache and Pain | 2019年 / 20卷
关键词：
COMPEL; Daily headache; Disability; Migraine; OnabotulinumtoxinA; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] ONABOTULINUMTOXINA IN CHRONIC MIGRAINE; PREDICTING RESPONSE TO TREATMENT BASED ON HEADACHE DAYS AT BASELINE
    Khalil, M.
    Buture, A.
    Nimeri, R.
    Ahmed, F.
    CEPHALALGIA, 2016, 36 : 118 - 119
  • [22] ONABOTULINUMTOXINA IN CHRONIC MIGRAINE; PREDICTING RESPONSE TO TREATMENT BASED ON HEADACHE DAYS AT BASELINE
    Kalaitzaki, S.
    Papantonakis, E.
    Panagopoulos, G.
    Tsiara, S.
    CEPHALALGIA, 2016, 36 : 118 - 118
  • [23] ONABOTULINUMTOXINA IN CHRONIC MIGRAINE; PREDICTING RESPONSE TO TREATMENT BASED ON HEADACHE DAYS AT BASELINE
    Khalil, M.
    Tanvir, T.
    Buture, A.
    Ahmed, F.
    CEPHALALGIA, 2018, 38 : 91 - 92
  • [24] Effect of OnabotulinumtoxinA on the Frequency and Impact of Headaches in Patients with Chronic Migraine with or without a History of Acute Pain Medication Overuse: Results of the COMPEL Study
    Tepper, Stewart J.
    Wilson, Maria-Carmen
    Rothrock, John F.
    Orejudos, Amelia
    Adams, Aubrey Manack
    Blumenfeld, Andrew M.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [25] EFFECT OF ONABOTULINUMTOXINA ON THE FREQUENCY AND IMPACT OF HEADACHES IN PATIENTS WITH CHRONIC MIGRAINE WITH OR WITHOUT A HISTORY OF ACUTE PAIN MEDICATION OVERUSE: RESULTS OF THE COMPEL STUDY
    Tepper, S. J.
    Wilson, M-C.
    Rothrock, J. F.
    Orejudos, A.
    Adams, A. Manack
    Blumenfeld, A. M.
    CEPHALALGIA, 2018, 38 : 71 - 72
  • [26] Effects of OnabotulinumtoxinATreatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Headache Every Day: A COMPEL Subanalysis
    Lopez, J.
    Blumenfeld, A. M.
    Young, W. B.
    Manack, Adams A.
    Rothrock, J. F.
    HEADACHE, 2017, 57 : 166 - 167
  • [27] Responder Rates to OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the COMPEL Study
    Rothrock, John F.
    Luo, Lei
    Eross, Eric
    Sommer, Katherine
    Blumenfeld, Andrew M.
    NEUROLOGY, 2020, 94 (15)
  • [28] Responder Rates to OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the COMPEL Study
    Rothrock, J. F.
    Luo, L.
    Eross, E. J.
    Sommer, K.
    Blumenfeld, A. M.
    HEADACHE, 2020, 60 : 93 - 93
  • [29] EFFICACY AND SAFETY OF ONABOTULINUMTOXINA IN AN OPEN-LABEL STUDY FOR THE PROPHYLACTIC TREATMENT OF CHRONIC MIGRAINE IN ADULT PATIENTS: COMPEL
    Blumenfeld, A.
    Stark, R.
    Adams, A. Manack
    Orejudos, A.
    Aurora, S.
    CEPHALALGIA, 2016, 36 : 27 - 28
  • [30] Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL
    Blumenfeld, Andrew
    Stark, Richard
    Adams, Aubrey Manack
    Orejudos, Amelia
    Aurora, Sheena
    NEUROLOGY, 2017, 88
12345